A Phase 1/2 interventional study of PF-06801591 in Advanced Malignancies and Non-small-cell Lung Cancer, sponsored by Pfizer. Completed at 49 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-15.
Sponsored by Pfizer · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 158 studies in Carcinoma, Non-Small-Cell Lung by Pfizer — 15 open to participants now, 26 under way, 5 of them phase 3. Carcinoma, Non-Small-Cell Lung · Pfizer.
Among the 158 studies in Carcinoma, Non-Small-Cell Lung by Pfizer, this one is the 45th largest by enrollment of the 136 interventional ones that give a count, is one of 14 that started in 2020, is one of 13 in phase 1/2, and was the 94th registered.
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →15 of the 158 studies in Carcinoma, Non-Small-Cell Lung by Pfizer are open now, in 12 countries. Recruiting first, the newest first:
Pfizer · Sites in United States
Ages 18+
Pfizer · Sites in United States, Australia, China and 8 more countries
Ages 18+
Pfizer · Sites in United States, China, France and 6 more countries
Ages 18+
Pfizer · Sites in United States, Argentina, Australia and 17 more countries
Ages 18+
Pfizer · Sites in United States, Argentina, Australia and 26 more countries
Ages 18+
By country, each count listing its studies:
Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
158 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 69 · Phase 2 58 · Phase 3 18 · Phase 4 4
First in 1999; this study’s year is marked. 14 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 155 is above the median of 62 across 6,024 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 79 across the 136 interventional studies, 97 across the 17 observational. Of the 123 that completed or were terminated, 70 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
4 of the studies in Carcinoma, Non-Small-Cell Lung by Pfizer that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07567352PfizerA Study to Learn About Patients With Non-Small Cell Lung Cancer (NSCLC) Who Took Lorlatinib as Their First Treatment | 2027-03-01 |
| NCT04389632Seagen, a wholly owned subsidiary of PfizerA Study of Sigvotatug Vedotin in Advanced Solid Tumors | 2027-06-16 |
| NCT05538130PfizerA Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors | 2027-08-31 |
| NCT05355701PfizerA Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations. | 2027-08-31 |
Add all 4 to your calendar (.ics) → With an account.
Among the 158 studies in Carcinoma, Non-Small-Cell Lung by Pfizer, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Phase 1b/2 protocol to evaluate pharmacokinetics, safety, efficacy, and pharmacodynamics of PF-06801591, a programmed death-1(PD-1) antagonist monoclonal antibody (mAb) in participants with advanced malignancies.
This study consists of 2 parts:
Phase 1b part (dose escalation and dose expansion) in patients with advanced malignancies in Asia and a global Phase 2 part in non small cell lung cancer (NSCLC) patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: PF-06801591
Drug: PF-06801591
Drug: PF-06801591
Drug: PF-06801591
A monoclonal antibody (mAb) that blocks the interaction between PD-1 and PDL1/ PD-L2.
Phase 1b: Number of Participants With Dose-Limiting Toxicities (DLT)
This study included Asian participants with advanced solid tumors (Phase 1b) and global participants with first line (1L) and second line (2L) non-small cell lung cancer (NSCLC) (Phase 2). For the Phase 1b, any of the following AEs occurring during the DLT observation period (the first cycle of treatment) which were attributable to the investigational product were classified as DLTs: Grade 5 AE not clearly due to the underlying disease or extraneous causes; Hematologic toxicity; Non-Hematologic Toxicity; Delay of ≥ 3 weeks in receiving the next scheduled administration due to persisting treatment-related toxicities.
Time frame: Phase 1b: at the end of cycle 1 (28 days) for the PF-06801591 300 mg SC Q4W arms, and (42 days) for the PF-06801591 600 mg SC Q6W arms
Phase 2: AUCτ of PF-06801591 at Steady State
This study included Asian participants with advanced solid tumors (Phase 1b) and global participants with 1L and 2L NSCLC (Phase 2). AUCτ is area under the plasma concentration-time profile from time zero to the next dose (at steady state, starting at Week 12). (τ = X days, where X = 28 days for Q4W regimen and 42 days for Q6W regimen)
Time frame: Phase 2: Cycle 4 Day 1, 8, 15, 22 and Cycle 5 Day 1 for the PF-06801591 300 mg SC Q4W arm, and Cycle 3 Day 1, 8, 15, 29 and Cycle 4 Day 1 for the PF-06801591 600 mg SC Q6W arm
Phase 2: Ctrough of PF-06801591 at Steady State, at Week 12
This study included Asian participants with advanced solid tumors (Phase 1b) and global participants with 1L and 2L NSCLC (Phase 2). Steady state Ctrough is pre-dose concentration following multiple dosing at steady state (Week 12)
Time frame: Phase 2: Cycle 4 Day 1 for the PF-06801591 300 mg SC Q4W arm, and Cycle 3 Day 1 for the PF-06801591 600 mg SC Q6W arm
Number of Participants With Treatment-Emergent Adverse Events
This study included Asian participants with advanced solid tumors (Phase 1b) and global participants with 1L and 2L NSCLC (Phase 2). An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.
Time frame: Phase 1b/2: On-treatment period is defined as the time from the first dose of study treatment through minimum (30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day).
Number of Participants With Laboratory Abnormalities
Laboratory results were classified according to the NCI-CTCAE criteria version 5.0. Grade 1: asymptomatic or mild symptoms, clinical or diagnostic observations only, intervention not indicated; Grade 2: moderate, minimal, local or noninvasive intervention indicated, limiting age-appropriate instrumental activities of daily life (ADL); Grade 3: severe or medically significant but not immediately life-threatening, hospitalization or prolongation of existing hospitalization indicated, disabling, limiting self-care (ADL); Grade 4: life-threatening consequence, urgent intervention indicated; Grade 5: death related to AE. Number of participants with Grade 1 to Grade 4 laboratory abnormalities were reported.
Time frame: Phase 1b/2: On-treatment period is defined as the time from the first dose of study treatment through minimum (30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day).
Pharmacokinetic Parameters: AUCτ After First Dose
This study included Asian participants with advanced solid tumors (Phase 1b) and global participants with 1L and 2L NSCLC (Phase 2). AUCτ is area under the plasma concentration-time profile from time zero to the next dose (after single dose). (τ = X days, where X = 28 days for Q4W regimen and 42 days for Q6W regimen)
Time frame: Phase 1b/2: For the PF-06801591 300 mg SC Q4W arms, Cycle 1 Day 1, 8, 15, 22, Cycle 2 Day 1; for the PF-06801591 600 mg SC Q6W arms, Cycle 1 Day 1, 8, 15, 29, Cycle 2 Day 1
Pharmacokinetic Parameters: Ctrough After First Dose
This study included Asian participants with advanced solid tumors (Phase 1b) and global participants with 1L and 2L NSCLC (Phase 2). Ctrough is pre-dose concentration after single dose (first dose).
Time frame: Phase 1b/2: Cycle 2 Day 1 for all Arms
Pharmacokinetic Parameters: Ctrough at Steady State
This study included Asian participants with advanced solid tumors (Phase 1b) and global participants with 1L and 2L NSCLC (Phase 2). Steady state Ctrough is pre-dose concentration following multiple dosing at steady state (Week 12)
Time frame: Phase 1b/2: For the PF-06801591 300 mg SC Q4W arms, Day 1 of Cycle 4; for the PF-06801591 600 mg SC Q6W arms, Day 1 of Cycle 3
Number of Participants With Treatment-Induced Anti-Drug Antibody (ADA) /Neutralizing Antibodies (NAb)
This study included Asian participants with advanced solid tumors (Phase 1b) and global participants with 1L and 2L NSCLC (Phase 2). Treatment-induced ADA = Baseline ADA titer was missing or negative and participant had ≥1 post-treatment positive ADA titer (ADA titer greater than or equal to 99 with assay cut-point of 1.09). Treatment-induced NAb = Baseline NAb titer was missing or negative or ADA-negative and participant had ≥1 post-treatment positive NAb titer.
Time frame: Phase 1b/2: Day 1 of Cycle 1, 2, 3, 4, 6, 8, 10 and end of treatment (EOT) for the PF-06801591 300 mg SC Q4W arms; Day 1 of Cycle 1, 2, 3, 4, 5, 7 and EOT for the PF-06801591 600 mg SC Q6W arms
Number of Participants With Objective Response (OR)
This study included Asian participants with advanced solid tumors (Phase 1b) and global participants with 1L and 2L NSCLC (Phase 2). OR was defined as confirmed best overall response (BOR) of complete response (CR) or partial response (PR) according to RECIST v1.1. Complete Response (CR): Complete disappearance of all target lesions with the exception of nodal disease. All target nodes must decrease to normal size (short axis \<10 mm). All target lesions must be assessed. Partial Response (PR): Greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. All target lesions must be assessed.
Time frame: Phase 1b/2: Up to 30 months
Time to Response (TTR)
This study included Asian participants with advanced solid tumors (Phase 1b) and global participants with 1L and 2L NSCLC (Phase 2). TTR was defined for participants with confirmed objective response (CR or PR) as the time from the 'start date' to the date of first documentation of objective tumor response which is subsequently confirmed.
Time frame: Phase 1b/2: Up to 30 months
Number of Participants With Objective Response (Complete Response + Partial Response) Reported by Baseline Programmed Death-Ligand 1 (PD-L1) Status (High, Low, and Unknown)
This study included Asian participants with advanced solid tumors (Phase 1b) and global participants with 1L and 2L NSCLC (Phase 2). OR was defined as confirmed BOR of CR or PR according to RECIST v1.1. CR: Complete disappearance of all target lesions with the exception of nodal disease. All target nodes must decrease to normal size (short axis \<10 mm). All target lesions must be assessed. PR: Greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. All target lesions must be assessed. PD-L1 expression was defined as the number of PD-L1 positive cells and/or qualitative assessment of PD-L1 staining on tumor and inflammatory cells in regions of interest that are defined by tumor cell morphology.
Time frame: Phase 1b/2: Baseline up to 30 months
| Milestone | Phase 1b Escalation 300 mg SC Q4W | Phase 1b Expansion 300 mg SC Q4W | Phase 1b Escalation 600 mg SC Q6W | Phase 1b Expansion 600 mg SC Q6W | Phase 2 300 mg SC Q4W | Phase 2 600 mg SC Q6W |
|---|---|---|---|---|---|---|
| Started | 4 | 12 | 6 | 12 | 41 | 80 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 4 | 12 | 6 | 12 | 41 | 80 |
| Withdrew: Adverse event | 0 | 2 | 1 | 0 | 1 | 3 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 8 | 8 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Progressive disease | 3 | 3 | 5 | 7 | 20 | 38 |
| Withdrew: Global deterioration of health status | 0 | 2 | 0 | 0 | 2 | 8 |
| Withdrew: Withdrawal by subject | 1 | 2 | 0 | 0 | 3 | 5 |
| Withdrew: Other unspecified | 0 | 0 | 0 | 0 | 0 | 2 |
| Withdrew: Ongoing | 0 | 3 | 0 | 5 | 7 | 15 |
| Milestone | Phase 1b Escalation 300 mg SC Q4W | Phase 1b Expansion 300 mg SC Q4W | Phase 1b Escalation 600 mg SC Q6W | Phase 1b Expansion 600 mg SC Q6W | Phase 2 300 mg SC Q4W | Phase 2 600 mg SC Q6W |
|---|---|---|---|---|---|---|
| Started | 3 | 9 | 6 | 7 | 20 | 49 |
| Completed | 3 | 8 | 4 | 2 | 9 | 22 |
| Not completed | 0 | 1 | 2 | 5 | 11 | 27 |
| Withdrew: Death | 0 | 0 | 1 | 2 | 8 | 20 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 2 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Other unspecified | 0 | 1 | 0 | 0 | 0 | 3 |
| Withdrew: Ongoing | 0 | 0 | 1 | 3 | 2 | 2 |
This study included Asian participants with advanced solid tumors (Phase 1b) and global participants with first line (1L) and second line (2L) non-small cell lung cancer (NSCLC) (Phase 2). For the Phase 1b, any of the following AEs occurring during the DLT observation period (the first cycle of treatment) which were attributable to the investigational product were classified as DLTs: Grade 5 AE not clearly due to the underlying disease or extraneous causes; Hematologic toxicity; Non-Hematologic Toxicity; Delay of ≥ 3 weeks in receiving the next scheduled administration due to persisting treatment-related toxicities.
| Participants | Phase 1b Escalation 300 mg SC Q4W | Phase 1b Expansion 300 mg SC Q4W | Phase 1b Escalation 600 mg SC Q6W | Phase 1b Expansion 600 mg SC Q6W |
|---|---|---|---|---|
| Phase 1b: Number of Participants With Dose-Limiting Toxicities (DLT) | 0 | 0 | 0 | 0 |
This study included Asian participants with advanced solid tumors (Phase 1b) and global participants with 1L and 2L NSCLC (Phase 2). AUCτ is area under the plasma concentration-time profile from time zero to the next dose (at steady state, starting at Week 12). (τ = X days, where X = 28 days for Q4W regimen and 42 days for Q6W regimen)
| microgram*hour per milliliter (μg*hr/mL) | Phase 2 300 mg SC Q4W | Phase 2 600 mg SC Q6W |
|---|---|---|
| Phase 2: AUCτ of PF-06801591 at Steady State | 20800 ± 54 | 48090 ± 47 |
This study included Asian participants with advanced solid tumors (Phase 1b) and global participants with 1L and 2L NSCLC (Phase 2). Steady state Ctrough is pre-dose concentration following multiple dosing at steady state (Week 12)
| microgram per milliliter (μg/mL) | Phase 2 300 mg SC Q4W | Phase 2 600 mg SC Q6W |
|---|---|---|
| Phase 2: Ctrough of PF-06801591 at Steady State, at Week 12 | 21.48 ± 60 | 23.95 ± 74 |
This study included Asian participants with advanced solid tumors (Phase 1b) and global participants with 1L and 2L NSCLC (Phase 2). An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.
Results for this outcome have not been posted.
Laboratory results were classified according to the NCI-CTCAE criteria version 5.0. Grade 1: asymptomatic or mild symptoms, clinical or diagnostic observations only, intervention not indicated; Grade 2: moderate, minimal, local or noninvasive intervention indicated, limiting age-appropriate instrumental activities of daily life (ADL); Grade 3: severe or medically significant but not immediately life-threatening, hospitalization or prolongation of existing hospitalization indicated, disabling, limiting self-care (ADL); Grade 4: life-threatening consequence, urgent intervention indicated; Grade 5: death related to AE. Number of participants with Grade 1 to Grade 4 laboratory abnormalities were reported.
Results for this outcome have not been posted.
This study included Asian participants with advanced solid tumors (Phase 1b) and global participants with 1L and 2L NSCLC (Phase 2). AUCτ is area under the plasma concentration-time profile from time zero to the next dose (after single dose). (τ = X days, where X = 28 days for Q4W regimen and 42 days for Q6W regimen)
Results for this outcome have not been posted.
This study included Asian participants with advanced solid tumors (Phase 1b) and global participants with 1L and 2L NSCLC (Phase 2). Ctrough is pre-dose concentration after single dose (first dose).
Results for this outcome have not been posted.
This study included Asian participants with advanced solid tumors (Phase 1b) and global participants with 1L and 2L NSCLC (Phase 2). Steady state Ctrough is pre-dose concentration following multiple dosing at steady state (Week 12)
Results for this outcome have not been posted.
This study included Asian participants with advanced solid tumors (Phase 1b) and global participants with 1L and 2L NSCLC (Phase 2). Treatment-induced ADA = Baseline ADA titer was missing or negative and participant had ≥1 post-treatment positive ADA titer (ADA titer greater than or equal to 99 with assay cut-point of 1.09). Treatment-induced NAb = Baseline NAb titer was missing or negative or ADA-negative and participant had ≥1 post-treatment positive NAb titer.
Results for this outcome have not been posted.
This study included Asian participants with advanced solid tumors (Phase 1b) and global participants with 1L and 2L NSCLC (Phase 2). OR was defined as confirmed best overall response (BOR) of complete response (CR) or partial response (PR) according to RECIST v1.1. Complete Response (CR): Complete disappearance of all target lesions with the exception of nodal disease. All target nodes must decrease to normal size (short axis \<10 mm). All target lesions must be assessed. Partial Response (PR): Greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. All target lesions must be assessed.
Results for this outcome have not been posted.
This study included Asian participants with advanced solid tumors (Phase 1b) and global participants with 1L and 2L NSCLC (Phase 2). TTR was defined for participants with confirmed objective response (CR or PR) as the time from the 'start date' to the date of first documentation of objective tumor response which is subsequently confirmed.
Results for this outcome have not been posted.
This study included Asian participants with advanced solid tumors (Phase 1b) and global participants with 1L and 2L NSCLC (Phase 2). OR was defined as confirmed BOR of CR or PR according to RECIST v1.1. CR: Complete disappearance of all target lesions with the exception of nodal disease. All target nodes must decrease to normal size (short axis \<10 mm). All target lesions must be assessed. PR: Greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. All target lesions must be assessed. PD-L1 expression was defined as the number of PD-L1 positive cells and/or qualitative assessment of PD-L1 staining on tumor and inflammatory cells in regions of interest that are defined by tumor cell morphology.
Results for this outcome have not been posted.
Collected over Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Phase 1b Escalation 300 mg SC Q4W | 0/4 (0%) | 1/4 (25%) | 4/4 (100%) |
| Phase 1b Expansion 300 mg SC Q4W | 0/12 (0%) | 2/12 (16.7%) | 11/12 (91.7%) |
| Phase 1b Escalation 600 mg SC Q6W | 1/6 (16.7%) | 0/6 (0%) | 6/6 (100%) |
| Phase 1b Expansion 600 mg SC Q6W | 2/12 (16.7%) | 0/12 (0%) | 12/12 (100%) |
| Phase 2 300 mg SC Q4W | 16/41 (39%) | 16/41 (39%) | 40/41 (97.6%) |
| Phase 2 600 mg SC Q6W | 31/80 (38.8%) | 13/80 (16.3%) | 58/80 (72.5%) |
| Event | Phase 1b Escalation 300 mg SC Q4W | Phase 1b Expansion 300 mg SC Q4W | Phase 1b Escalation 600 mg SC Q6W | Phase 1b Expansion 600 mg SC Q6W | Phase 2 300 mg SC Q4W | Phase 2 600 mg SC Q6W |
|---|---|---|---|---|---|---|
| Tubulointerstitial nephritisRenal and urinary disorders | 1/4 | 0/12 | 0/6 | 0/12 | 0/41 | 0/80 |
| Disease progressionGeneral disorders | 0/4 | 0/12 | 0/6 | 0/12 | 4/41 | 2/80 |
| VertigoEar and labyrinth disorders | 0/4 | 1/12 | 0/6 | 0/12 | 0/41 | 0/80 |
| Pancreatitis acuteGastrointestinal disorders | 0/4 | 1/12 | 0/6 | 0/12 | 0/41 | 0/80 |
| PneumoniaInfections and infestations | 0/4 | 1/12 | 0/6 | 0/12 | 2/41 | 2/80 |
| MyalgiaMusculoskeletal and connective tissue disorders | 0/4 | 1/12 | 0/6 | 0/12 | 0/41 | 0/80 |
| AnaemiaBlood and lymphatic system disorders | 0/4 | 0/12 | 0/6 | 0/12 | 2/41 | 0/80 |
| Lung neoplasm malignantNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/4 | 0/12 | 0/6 | 0/12 | 2/41 | 0/80 |
| COVID-19 pneumoniaInfections and infestations | 0/4 | 0/12 | 0/6 | 0/12 | 0/41 | 2/80 |
| Ventricular extrasystolesCardiac disorders | 0/4 | 0/12 | 0/6 | 0/12 | 1/41 | 0/80 |
| Event | Phase 1b Escalation 300 mg SC Q4W | Phase 1b Expansion 300 mg SC Q4W | Phase 1b Escalation 600 mg SC Q6W | Phase 1b Expansion 600 mg SC Q6W | Phase 2 300 mg SC Q4W | Phase 2 600 mg SC Q6W |
|---|---|---|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 1/4 | 4/12 | 0/6 | 6/12 | 8/41 | 10/80 |
| PruritusSkin and subcutaneous tissue disorders | 1/4 | 3/12 | 3/6 | 2/12 | 1/41 | 6/80 |
| Blood glucose increasedInvestigations | 0/4 | 0/12 | 0/6 | 4/12 | 0/41 | 0/80 |
| HypertriglyceridaemiaMetabolism and nutrition disorders | 0/4 | 4/12 | 0/6 | 2/12 | 0/41 | 0/80 |
| HypoalbuminaemiaMetabolism and nutrition disorders | 0/4 | 4/12 | 0/6 | 3/12 | 2/41 | 2/80 |
| HypokalaemiaMetabolism and nutrition disorders | 0/4 | 4/12 | 0/6 | 2/12 | 0/41 | 1/80 |
| HyperthyroidismEndocrine disorders | 1/4 | 0/12 | 0/6 | 0/12 | 1/41 | 0/80 |
| HypothyroidismEndocrine disorders | 1/4 | 0/12 | 1/6 | 0/12 | 1/41 | 5/80 |
| DiarrhoeaGastrointestinal disorders | 1/4 | 0/12 | 0/6 | 0/12 | 3/41 | 1/80 |
| ToothacheGastrointestinal disorders | 1/4 | 0/12 | 0/6 | 0/12 | 0/41 | 0/80 |
| Age, Continuous(Years) | Phase 1b Escalation 300 mg SC Q4W | Phase 1b Expansion 300 mg SC Q4W | Phase 1b Escalation 600 mg SC Q6W | Phase 1b Expansion 600 mg SC Q6W | Phase 2 300 mg SC Q4W | Phase 2 600 mg SC Q6W | Total |
|---|---|---|---|---|---|---|---|
| Mean | 62.0 ± 13.29 | 57.3 ± 15.78 | 62.7 ± 10.33 | 62.4 ± 10.02 | 63.9 ± 11.75 | 62.9 ± 10.62 | 62.6 ± 11.33 |
| Age, Customized(Participants) | Phase 1b Escalation 300 mg SC Q4W | Phase 1b Expansion 300 mg SC Q4W | Phase 1b Escalation 600 mg SC Q6W | Phase 1b Expansion 600 mg SC Q6W | Phase 2 300 mg SC Q4W | Phase 2 600 mg SC Q6W | Total |
|---|---|---|---|---|---|---|---|
| <65 years | 2 | 7 | 4 | 6 | 18 | 48 | 85 |
| 65 - <75 years | 1 | 5 | 1 | 4 | 17 | 21 | 49 |
| 75 - <85 years | 1 | 0 | 1 | 2 | 5 | 10 | 19 |
| ≥85 years | 0 | 0 | 0 | 0 | 1 | 1 | 2 |
| Sex: Female, Male(Participants) | Phase 1b Escalation 300 mg SC Q4W | Phase 1b Expansion 300 mg SC Q4W | Phase 1b Escalation 600 mg SC Q6W | Phase 1b Expansion 600 mg SC Q6W | Phase 2 300 mg SC Q4W | Phase 2 600 mg SC Q6W | Total |
|---|---|---|---|---|---|---|---|
| Female | 4 | 6 | 3 | 3 | 9 | 14 | 39 |
| Male | 0 | 6 | 3 | 9 | 32 | 66 | 116 |
| Ethnicity (NIH/OMB)(Participants) | Phase 1b Escalation 300 mg SC Q4W | Phase 1b Expansion 300 mg SC Q4W | Phase 1b Escalation 600 mg SC Q6W | Phase 1b Expansion 600 mg SC Q6W | Phase 2 300 mg SC Q4W | Phase 2 600 mg SC Q6W | Total |
|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 4 | 12 | 6 | 12 | 41 | 80 | 155 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Phase 1b Escalation 300 mg SC Q4W | Phase 1b Expansion 300 mg SC Q4W | Phase 1b Escalation 600 mg SC Q6W | Phase 1b Expansion 600 mg SC Q6W | Phase 2 300 mg SC Q4W | Phase 2 600 mg SC Q6W | Total |
|---|---|---|---|---|---|---|---|
| White | 0 | 0 | 0 | 0 | 34 | 62 | 96 |
| Black or African American | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 4 | 12 | 6 | 12 | 7 | 18 | 59 |
| Multiracial | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from Mar 2020 to primary completion in Mar 2022, 23 months.
Results were first posted in May 2023, 1 year 2 months after primary completion.
Of 309 industry-sponsored phase 1/2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 77. This study's 23 months is below that.
Counting every sponsor, half of 432 studies reached it within 63 months; a quarter within 42 and three quarters within 80.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sasanlimab
Carcinoma, Non-Small-Cell Lung →